loader
Please Wait
Applying Filters...

Annual Sales of Ribociclib reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 30,563Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Kisqali

PharmaCompass

01

Brand Name : Kisqali

Ribociclib

arrow
Discovery on Target
Not Confirmed

Brand Name : Kisqali

arrow
Discovery on Target
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 687

2019 Revenue in Millions : 480

Growth (%) : 43

blank

02

Brand Name : Kisqali

Ribociclib

arrow
Discovery on Target
Not Confirmed

Brand Name : Kisqali

arrow
Discovery on Target
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 937

2020 Revenue in Millions : 687

Growth (%) : 36

blank

03

Brand Name : Kisqali

Ribociclib

arrow
Discovery on Target
Not Confirmed

Brand Name : Kisqali

arrow
Discovery on Target
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,231

2021 Revenue in Millions : 937

Growth (%) : 31

blank

04

Brand Name : Kisqali

Ribociclib

arrow
Discovery on Target
Not Confirmed

Brand Name : Kisqali

arrow
Discovery on Target
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 2,080

2022 Revenue in Millions : 1,231

Growth (%) : 69

blank

05

Brand Name : Kisqali

Ribociclib Succinate

arrow
Discovery on Target
Not Confirmed

Brand Name : Kisqali

arrow
Discovery on Target
Not Confirmed

Ribociclib Succinate

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 76

2016 Revenue in Millions : 0

Growth (%) : New Launch

blank

06

Brand Name : Kisqali

Ribociclib Succinate

arrow
Discovery on Target
Not Confirmed

07

Brand Name : Kisqali

Ribociclib

arrow
Discovery on Target
Not Confirmed

Brand Name : Kisqali

arrow
Discovery on Target
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 480

2018 Revenue in Millions : 235

Growth (%) : 104

blank